[Federal Register Volume 80, Number 245 (Tuesday, December 22, 2015)]
[Notices]
[Pages 79594-79595]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-32141]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of an Exclusive Start-Up Option License: Potent 
and Selective Analogues of Monamine Transporters; Methods of Making; 
and Uses Thereof

AGENCY: National Institutes of Health, Public Health Service, HHS.

[[Page 79595]]


ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is a notice, in accordance with 35 U.S.C. 209 and 37 CFR 
404, that the National Institute of Drug Abuse, National Institutes of 
Health, Department of Health and Human Services is contemplating the 
grant of an exclusive start-up option license to practice the 
inventions embodied in the following Patent Applications and all 
related continuing and foreign patents/patent applications for the 
technology family to EncepHeal Therapeutics, Inc., located in Winston-
Salem, North Carolina.

DATES: Only written comments and/or applications for a license which 
are received by the NCI Technology Transfer Center on or before January 
6, 2016 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
comments, and other materials relating to the contemplated exclusive 
license should be directed to Martha Lubet, Ph.D., Technology Transfer 
Specialist, NCI TTC, 9609 Medical Center Drive, Room IE350, and 
Rockville, MD 20850. Telephone: (240) 276-5508. Facsimile: (240) 276-
5505. Email: [email protected].

SUPPLEMENTARY INFORMATION: This invention concerns analogues of 
modafinil and methods of using the analogues for the treatment of 
substance use disorders and sleep disorders.
    The prospective exclusive start-up option license will be royalty 
bearing and will comply with the terms and conditions of 35 U.S.C. 209 
and 37 CFR part 404. The prospective exclusive start-up option may be 
granted unless within fifteen (15) days from the date of this published 
notice, the NCI receives written evidence and argument that establishes 
that the grant of the license would not be consistent with the 
requirements of 35 U.S.C. 209 and 37 CFR part 404.
    Complete applications for a license in the field of use filed in 
response to this notice will be treated as objections to the grant of 
the contemplated exclusive start-up option license. Comments and 
objections submitted to this notice will not be made available for 
public inspection and, to the extent permitted by law, will not be 
released under the Freedom of Information Act, 5 U.S.C. 552.
    Intellectual Property:
    U.S. provisional application 61/774,878, filed March 8, 2013 
entitled ``Potent and Selective Inhibitors of Monamine Transporters; 
Methods of Making; and Uses Thereof'' [HHS Ref. No. E-073-2013/0-US-
01];
    PCT application PCT/US2014/021514, filed March 7, 2014 entitled 
``Potent and Selective Analogues of: Monamine Transporters; Methods of 
Making; and Uses Thereof'' [HHS Ref. No. E-073-2013/0-PCT-02];
    U.S. application 14/772,486, filed September 3, 2015 entitled 
``Potent and Selective Analogues of Monamine Transporters; Methods of 
Making; and Uses Thereof'' [HHS Ref. No. E-073-2013/0-US-06];
    EPO application 14714043.8, filed September 1, 2015 entitled 
``Potent and Selective Analogues of Monamine Transporters; Methods of 
Making; and Uses Thereof'' [HHS Ref. No. E-073-2013/0-EP-05];
    Australian application 2014225550, filed September 8, 2015 entitled 
``Potent and Selective Analogues of Monamine Transporters; Methods of 
Making; and Uses Thereof'' [HHS Ref. No. E-073-2013/0-AU-03];
    Canadian application 2903746, filed September 2, 2015 entitled 
``Potent and Selective Analogues of Monamine Transporters; Methods of 
Making; and Uses Thereof'' [HHS Ref. No. E-073-2013/0-CA-04];
    The patent rights to these inventions have been assigned to and/or 
exclusively licensed to the Government of the United States of America.
    The prospective exclusive start-up option licensed territory may be 
worldwide and the field of use may be limited to: (a) Treatment of 
substance use disorders and/or (b) treatment of sleep disorders.
    Upon the expiration or termination of the exclusive start-up option 
license, EncepHeal Therapeutics, Inc. will have the exclusive right to 
execute a start-up exclusive commercialization license which will 
supersede and replace the exclusive start-up option license with no 
greater field of use and territory than granted in the exclusive start-
up option license.

    Dated: December 17, 2015.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer 
Institute.
[FR Doc. 2015-32141 Filed 12-21-15; 8:45 am]
 BILLING CODE 4140-01-P